Hideho Okada
Hideho Okada
Professor of Neurological Surgery
Verified email at - Homepage
Cited by
Cited by
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
DM O’Rourke, MLP Nasrallah, A Desai, JJ Melenhorst, K Mansfield, ...
Science translational medicine 9 (399), eaaa0984, 2017
Induction of CD8+ T-cell responses against novel glioma–associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and …
H Okada, P Kalinski, R Ueda, A Hoji, G Kohanbash, TE Donegan, ...
Journal of clinical oncology 29 (3), 330, 2011
Actively personalized vaccination trial for newly diagnosed glioblastoma
N Hilf, S Kuttruff-Coqui, K Frenzel, V Bukur, S Stevanović, ...
Nature 565 (7738), 240-245, 2019
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
H Okada, M Weller, R Huang, G Finocchiaro, MR Gilbert, W Wick, ...
The Lancet Oncology 16 (15), e534-e542, 2015
Classification of current anticancer immunotherapies
L Galluzzi, E Vacchelli, JM Bravo-San Pedro, A Buqué, L Senovilla, ...
Oncotarget 5 (24), 12472, 2014
Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma
LA Johnson, J Scholler, T Ohkuri, A Kosaka, PR Patel, SE McGettigan, ...
Science translational medicine 7 (275), 275ra22-275ra22, 2015
Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment
S Müller, G Kohanbash, SJ Liu, B Alvarado, D Carrera, A Bhaduri, ...
Genome biology 18, 1-14, 2017
COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor CellsCOX-2 Blockade and Gliomagenesis
M Fujita, G Kohanbash, W Fellows-Mayle, RL Hamilton, Y Komohara, ...
Cancer research 71 (7), 2664-2674, 2011
Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas
G Kohanbash, DA Carrera, S Shrivastav, BJ Ahn, N Jahan, T Mazor, ...
The Journal of clinical investigation 127 (4), 1425-1437, 2017
Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models
X Zhu, F Nishimura, K Sasaki, M Fujita, JE Dusak, J Eguchi, ...
Journal of translational medicine 5, 1-15, 2007
Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1
R Ueda, G Kohanbash, K Sasaki, M Fujita, X Zhu, ER Kastenhuber, ...
Proceedings of the National Academy of Sciences 106 (26), 10746-10751, 2009
Immunotherapeutic approaches for glioma
H Okada, G Kohanbash, X Zhu, ER Kastenhuber, A Hoji, R Ueda, M Fujita
Critical Reviews™ in Immunology 29 (1), 2009
STING Contributes to Antiglioma Immunity via Triggering Type I IFN Signals in the Tumor MicroenvironmentSTING-Mediated Antiglioma Immunity
T Ohkuri, A Ghosh, A Kosaka, J Zhu, M Ikeura, M David, SC Watkins, ...
Cancer immunology research 2 (12), 1199-1208, 2014
Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and …
IF Pollack, RI Jakacki, LH Butterfield, RL Hamilton, A Panigrahy, ...
Journal of Clinical Oncology 32 (19), 2050, 2014
GM-CSF Promotes the Immunosuppressive Activity of Glioma-Infiltrating Myeloid Cells through Interleukin-4 Receptor-αIL-4Rα+ Suppressive Myeloid Cells in Gliomas
G Kohanbash, K McKaveney, M Sakaki, R Ueda, AH Mintz, N Amankulor, ...
Cancer research 73 (21), 6413-6423, 2013
Novel and shared neoantigen derived from histone 3 variant H3. 3K27M mutation for glioma T cell therapy
ZS Chheda, G Kohanbash, K Okada, N Jahan, J Sidney, M Pecoraro, ...
Journal of Experimental Medicine 215 (1), 141-157, 2018
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy
X Zhu, M Fujita, LA Snyder, H Okada
Journal of neuro-oncology 104, 83-92, 2011
Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell–based therapeutics
JG Zhang, J Eguchi, CA Kruse, GG Gomez, H Fakhrai, S Schroter, W Ma, ...
Clinical Cancer Research 13 (2), 566-575, 2007
Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly …
T Tatsumi, J Huang, WE Gooding, A Gambotto, PD Robbins, ...
Cancer research 63 (19), 6378-6386, 2003
EphA2 as a glioma-associated antigen: a novel target for glioma vaccines
M Hatano, J Eguchi, T Tatsumi, N Kuwashima, JE Dusak, MS Kinch, ...
Neoplasia 7 (8), 717-722, 2005
The system can't perform the operation now. Try again later.
Articles 1–20